Canexis Pharma AG is continuously working to obtain further approvals for the production of active pharmaceutical ingredients (API) in accordance with the EU and PIC/S GMP.
The aim is to produce cannabis medicines in accordance with the applicable regulations and pharmacopoeias, which primarily includes the following works:
With the drug approvals, our product portfolio includes:
In order to always maintain the highest quality, Canexis relies on process knowledge, clean rooms and state-of-the-art systems. The entire value chain from the seedlings to the delivered raw materials is monitored by Canexis. Our in-house analytics support compliance with the highest quality from incoming goods inspection through all processes right up to release for shipping to our customers.
We would be happy to offer you suitable solutions in the area of medical cannabis.
Contact us for a non-binding consultation.
Canexis Pharma AG
Hauptstrasse 25
8255 Schlattingen
Switzerland
Stay up to date. In our newsletter we will inform you about our latest findings and developments. You will also gain exciting insights into our daily work.
©2024 Canexis AG
